Astellas NEXT step

Astellas UroLog

Domain Not Resolving

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Maps

WordPress

LetsEncrypt

Mobile Non Scaleable Content

US Privacy User Signal Mechanism

Sitelinks Search Box

General Counsel

Catherine Levitt

Chief Commercial Officer

Claus Zieler

Associate General Counsel, IP

James Lynch

President, Astellas US Technologies and Executive Director, Project and Product Management US1

John DeMay

Executive Director, Deputy General Counsel Investigations & Litigation (US, Japan, Greater China)

Lisa Kistler

President

Mark Reisenauer

Associate General Counsel

Meaghan Hanifin Dees

Executive Director, Deputy General Counsel

Michael Elm

Executive Director, Legal Commercial Lead US

Molly McCoy

Director, Global T&E and P2P Regional Process Owner (EMEA)

Nadeem Rajput

Ana C. Ward

Vice President - Head of Affiliate Engagement

Atsushi Kamide

Corporate Executive

Toshihiko Iwata

Takeru Furuya

Associate Director, Medicinal Chemistry

Kenji Sumi

Elizabeth Oubre

Manager, Marketing Operations, Market Access & Commercial Capabilities

Yoshihiko Hatanaka

Representative Director, President and Chief Executive Officer

Amanda Hart

Head, Global Business and Market Analytics

Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.

Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.

FibroGen uses its expertise in CTGF and HIF biology to discover, develop, and commercialize novel therapeutics.

Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions.

Biotechnology Public Companies With More Than 500 Employees

City of Tokyo Health Care Companies

City of Tokyo Public Companies With More Than 1000 Employees

Medical Public Companies With More Than $500 in Revenue

At Astellas, our vision is to be at the forefront of healthcare change by turning innovative science into meaningful VALUE for patients. As a specialty global pharmaceutical company, we focus on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. Together with our partners, we aim to lead in the areas where we can deliver the greatest value, with a focus on immuno-oncology, gene therapy, mitochondria, blindness and regeneration and targeted protein degradation.
Astellas operates its business in approximately 70 countries around the world. It has approximately 14,000 employees, and its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation. In its FY2022 financial results, revenue achieved about 1,500 billion yen (ca.$11 billion*), and R&D expenses were about 280 billion yen (ca.$2.0 billion*).

*The exchange rate for the yen, 1USD: 142yen

National Institute on Drug Abuse (NIDA)

Grant - Astellas Pharma

Tokyo

Japan

Asia

Astellas Pharma

Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management

FDA rejects Astellas’ effort to support longer use of eye drug Izervay

Astellas receives Complete Response Letter from FDA for Izervay sNDA

Protein Engineering Market Projected to Reach USD 7.39 Billion by 2032 with a CAGR of 14.72% - SNS Insider

Muscle Invasive Bladder Cancer Therapeutics Market Size Expected to Hit USD 4.09 Bn by 2032, Expanding at a 15.2% CAGR:

In-Depth Analysis Of The Global Immunosuppressants Market: Key Drivers, Trends, Opportunities, And Forecast 2024-2033

Chronic Lower Back Pain (CLBP) Market Size on Track to Surpass USD 5.52 Billion by 2032 at a 9.2% CAGR | VMR

First preclinical data on ASP-1002 for the treatment of solid tumors

Astellas Pharma reports H1 results (Pink Limited Info:ALPMF)

Astellas withdraws its EU MAA for geographic atrophy

United States

North America

Austria

Europe

France

Spain

HTML5

.NET 4.5

Vimeo

Google Analytics

Bootstrap

Cloudflare CDN

Microsoft Outlook

Google Tag Manager

Amazon EC2

F5 NGINX

Astellas Pharma owns Astellas Venture Management

Astellas Pharma owns Astellas Global Health Foundation

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

news impact assignment basic	general	Mar 8, 2024 2:07 PM	801b224e
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 2:07 PM	a25fe0f1
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	283346a5
crunchbase profile	general	Nov 25, 2024 11:39 AM	26b2e56c
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:15 PM	adca1162
peers	general
news basic	general	Mar 8, 2024 2:07 PM	8b530d3c
bundesanzeiger	filings
financials download nd	financials
private financials	financials

4503

COM:ASTELLAS

Astellas Pharma Inc.

Last Close

1,562.00

25/11 06:45

Market Cap

2.98T

Beta: -

Volume Today

14.54M

Avg: -